PromarkerD features at American Diabetes Association 79th Scientific Sessions saying diabetics deserve to know their future k...
June 06 2019 - 11:00PM
JCN Newswire (English)
|
- Proteomics International meeting with US tier 1
national diagnostic groups to expand global roll-out of PromarkerD
including EU and Mexico
|
SAN FRANCISCO, June 7, 2019 - (ACN Newswire) -
Proteomics International (ASX: PIQ) has been invited to feature on
the American Diabetes Association (ADA) TV News Network as a key
opinion leader (KOL) on diabetic kidney disease diagnostics, which
includes an update on PromarkerD, during the ADA 79th Scientific
Sessions conference in San Francisco, June 7-11, 2019.
PromarkerD will also be presented at booth 1738 in the ADA 79th
Scientific Sessions Exhibit Hall. PromarkerD is a blood test that
can diagnose and predict whether a patient will develop diabetic
kidney disease, and predict the onset of diabetic kidney disease
before clinical symptoms appear.
PromarkerD clinical data, first launched at the American Diabetes
Association Annual Scientific Sessions 2017 and published in the
prestigious journal Diabetes Care, shows PromarkerD correctly
predicted 86% of otherwise healthy diabetics who went on to develop
chronic kidney disease within four years.
Proteomics International Managing Director Dr Richard Lipscombe
outlined the impact PromarkerD will have saving lives and
healthcare costs, and the global roll-out plans for PromarkerD in
the exclusive interview to be broadcast at the industry's leading
conference.
See the interview here: http://bit.ly/PromarkerD-ADA /
https://youtu.be/X_KScqaqpvc
"PromarkerD is world-beating technology and needs to get into the
hands of specialists and physicians to stem the tsunami of kidney
disease which is causing over 40,000 deaths per year in the US,
with related healthcare spending exceeding US$100 billion
annually," commented Dr Lipscombe.
"There is nothing else like PromarkerD available - it's the world's
leading predictive test for diabetic kidney disease according to
analysts in our sector."
He said the test will also make a major difference for insurance
companies because it will cut dramatically the number of people who
are unaware they have progressive kidney disease so they can do
something about it immediately, and so reduce treatments costs.
"The US population with diabetes deserve to know their kidney
disease status."
There are approximately 260,000 CLIA certified laboratories in the
US, the majority of which have diagnostic capabilities to license
the PromarkerD test.
PromarkerD has been rated the world's leading diagnostic test for
diabetic kidney disease by global research house Frost &
Sullivan in its independent industry report titled 'Biomarkers
Enabling Diabetes and Obesity Management.'
PromarkerD has received patent protection in several major
jurisdictions including the USA, China, Europe, and Japan, with
others pending.
The Test
The immunoassay reagents for PromarkerD can be configured into a
Laboratory Developed Test (LDT) for use by certified
laboratories.
This parallels the LDT using the existing mass spectrometry
platform, and offers a better fit for mainstream diagnostics
providers where the immunoassay platform is more standard than
advanced mass spectrometry technology.
The dual technology platforms offer greater choice to the large
market of certified clinical laboratories that conduct these types
of test.
In parallel with the fast roll-out of PromarkerD using the
Laboratory Developed Test route, Proteomics International is also
pursuing registration of the kit version of the test for larger
scale adoption as market demand increases.
About PromarkerD (www.PromarkerD.com)
PromarkerD is a predictive diagnostic test for diabetic kidney
disease. In clinical studies presented at the American Diabetes
Association Annual Scientific Sessions [ASX: 13 June 2017] and
published in the prestigious journal Diabetes Care [ASX: 6
September 2017], PromarkerD correctly predicted 86% of otherwise
healthy diabetics who went on to develop chronic kidney disease
within four years. www.PromarkerD.com
PromarkerD has been rated the world's leading diagnostic test for
diabetic kidney disease by the global research house Frost &
Sullivan in its report titled Biomarkers Enabling Diabetes and
Obesity Management [ASX: 27 March 2017]. PromarkerD has received
patent protection in several major jurisdictions including the USA,
China, Europe, and Japan, with others pending. Further information
is available through the PromarkerD web portal.
Proteomics International Laboratories Ltd (PILL)
(www.proteomicsinternational.com)
Proteomics International (ASX: PIQ) is a medtech company at the
forefront of predictive diagnostics and bio-analytical services.
The company specialises in the area of proteomics - the industrial
scale study of the structure and function of proteins. It received
the world's first ISO 17025 laboratory accreditation for proteomics
services, and operates from state-of-the-art facilities on the QEII
Medical Campus in Perth, W. Australia.
Proteomics International's business model is centred on the
commercialisation of the company's world-leading test for diabetic
kidney disease, PromarkerD. The company offsets the cash burn from
R&D and product development through provision of specialist
analytical services, whilst using its proprietary Promarker(TM)
technology platform to create a pipeline of novel diagnostic
tests.
Please contact:
Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
Chuck Morrison
Head of Business Development
Proteomics International
T: +1 617 331 2975
E: c.morrison@proteomicsinternational.com
Susan Fitzpatrick-Napier
Public Relations & Media Contact
Digital Mantra Group
T: +61 2 8218 2144 or +1 415-951-3228
E: team@dmgpr.com
Source: Proteomics International Laboratories Ltd (PILL)
Copyright 2019 ACN Newswire . All rights reserved. |
Proteomics International... (ASX:PIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteomics International... (ASX:PIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024